Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 5/2016

01-09-2016 | Review Article

Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review

Authors: Dinesh Jothimani, Sanjay Govil, Mohamed Rela

Published in: Hepatology International | Issue 5/2016

Login to get access

Abstract

Recurrent HCV infection (rHCV) of the liver allograft following transplantation is universal and is associated with poor graft and patient survival in comparison with other indications. Treatment of rHCV infection in the previous era with pegylated interferon and ribavirin was associated with low sustained virological response (SVR) due to poor tolerability, adverse events and graft rejection. Recently, directly acting antiviral drugs (DAA) have been approved for the treatment of hepatitis C infection and a number of clinical trials have been conducted across various centers in the management of rHCV infection of the graft. In this review we discuss about recent studies that have emerged on the use of NS5b polymerase inhibitor, sofosbuvir in combination with second generation protease inhibitor, simeprevir, fixed dose ledipasvir or daclatasvir with or without ribavirin in the treatment of post transplant rHCV infection.
Literature
1.
Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349(9055):825–832
2.
Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997;26(3 Suppl 1):34S–38S
3.
Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27(5):1435–1440
4.
Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112(2):463–472
5.
Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999;29(4):1311–1316
6.
Matas AJ, Smith JM, Skeans MA, Lamb KE, Gustafson SK, Samana CJ, Stewart DE, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2011 Annual Data Report: kidney. Am J Transplant. 2013 Jan;13 Suppl 1:11–46
7.
Adam R, McMaster P, O'Grady JG, et al. Evolution of liver transplantation in Europe: report of the European liver transplant registry. Liver Transplant 2003;9(12):1231–1243.
8.
Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. New Engl J Med 1996;334(13):815–820
9.
Samuel D, Feray C. Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues. J Viral Hepat 2000;7(2):87–92
10.
Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36(1):202–210
11.
Terrault NA. Hepatitis C virus and liver transplantation. Seminars in gastrointestinal disease. 2000;11(2):96–114
12.
Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001;35(5):666–678
13.
Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35(3):680–687
14.
Ferrell LD, Wright TL, Roberts J, Ascher N, Lake J. Hepatitis C viral infection in liver transplant recipients. Hepatology 1992;16(4):865–876
15.
Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000;32(4):673–684
16.
Feray C, Gigou M, Samuel D, Paradis V, Wilber J, David MF, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994;20(5):1137–1143
17.
Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 2003;9(11):S28–S34
18.
Vinaixa C, Rubin A, Aguilera V, Berenguer M. Recurrence of hepatitis C after liver transplantation. Ann Gastroenterol Q Publ Hell Soc Gastroenterol 2013;26(4):304–313
19.
Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000;32(4 Pt 1):852–858
20.
Demetris AJ. Evolution of hepatitis C virus in liver allografts. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 2009;15 Suppl 2:S35–S41
21.
Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996;23(5):971–976
22.
Lim HL, Lau GK, Davis GL, Dolson DJ, Lau JY. Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C virus infection. Gastroenterology 1994;106(1):248–251
23.
Joshi D, Pinzani M, Carey I, Agarwal K. Recurrent HCV after liver transplantation-mechanisms, assessment and therapy. Nat Rev Gastroenterol Hepatol 2014;11(12):710–721
24.
Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 2008;14 Suppl 2:S36–S44
25.
Lai JC, Verna EC, Brown RS, Jr., O'Leary JG, Trotter JF, Forman LM, et al. Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology 2011;54(2):418–424
26.
Brandman D, Pingitore A, Lai JC, Roberts JP, Ferrell L, Bass NM, et al. Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 2011;17(12):1380–1386
27.
Ghabril M, Dickson RC, Krishna M, Machicao V, Aranda-Michel J, Bonatti H, et al. Explanted liver inflammatory grade predicts fibrosis progression in hepatitis C recurrence. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 2011;17(6):685–694
28.
Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28(3):823–830
29.
Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Ame J Gastroenterol 1997;92(9):1453–1457
30.
Schmitt TM, Phillips M, Sawyer RG, Northup P, Hagspiel KD, Pruett TL, et al. Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation. Dig Dis Sci 2010;55(11):3224–3234
31.
Caston JJ, Castells L, Varo E, Gomez MA, de la Mata M, Campos-Varela I, et al. Impact of Cytomegalovirus infection on severe hepatitis c recurrence in patients undergoing liver transplantation. Transplantation 2016;100(3):593–599
32.
Duclos-Vallee JC, Feray C, Sebagh M, Teicher E, Roque-Afonso AM, Roche B, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008;47(2):407–417
33.
Jain A, Singhal A, Kashyap R, Safadjou S, Ryan CK, Orloff MS. Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up. Transplantation 2011;92(4):453–460
34.
Dumortier J, Salame E, Roche B, Hurtova M, Conti F, Radenne S, et al. Severe fibrosis in patients with recurrent hepatitis C after liver transplantation: a French experience on 250 patients over 15 years (the Orfevre study). Clin Res Hepatol Gastroenterol 2014;38(3):292–299
35.
Dhanasekaran R, Sanchez W, Mounajjed T, Wiesner RH, Watt KD, Charlton MR. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int Off J Int Assoc Study Liver 2015;35(11):2433–2441
36.
Kawaoka T, Takahashi S, Kawakami Y, Tsuge M, Hiramatsu A, Imamura M, et al. Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation. Hepatol Res Off J Jpn Soc Hepatol 2015;45(11):1047–1054
37.
Barrault C, Roudot-Thoraval F, Tran Van Nhieu J, Atanasiu C, Kluger MD, Medkour F, et al. Non-invasive assessment of liver graft fibrosis by transient elastography after liver transplantation. Clin Res Hepatol Gastroenterol 2013;37(4):347–352
38.
Corradi F, Piscaglia F, Flori S, D'Errico-Grigioni A, Vasuri F, Tame MR, et al. Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver 2009;41(3):217–225
39.
Massoumi H, Elsiesy H, Khaitova V, Peterson B, Norkus E, Grewal P, et al. An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant. Transplantation 2009;88(5):729–735
40.
Heydtmann M, Freshwater D, Dudley T, Lai V, Palmer S, Hubscher S, et al. Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 2006;6(4):825–833
41.
Wang CC, Wang SH, Lin CC, Liu YW, Yong CC, Yang CH, et al. Liver transplantation from an uncontrolled non-heart-beating donor maintained on extracorporeal membrane oxygenation. Transplant Proc 2005;37(10):4331–4333
42.
Lodato F, Azzaroli F, Tame MR, Di Girolamo M, Buonfiglioli F, Mazzella N, et al. G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence. World J Gastroenterol WJG. 2009;15(43):5449–5454
43.
Forns X, Garcia-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003;39(3):389–396
44.
Singh N, Gayowski T, Wannstedt CF, Shakil AO, Wagener MM, Fung JJ, et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation 1998;65(1):82–86
45.
Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 2005;5(1):118–124
46.
Kuo A, Terrault NA. Management of hepatitis C in liver transplant recipients. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 2006;6(3):449–458
47.
Lodato F, Berardi S, Gramenzi A, Mazzella G, Lenzi M, Morelli MC, et al. Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. Alimenta Pharmacol Thera 2008;28(4):450–457
48.
Fernandez I, Meneu JC, Colina F, Garcia I, Munoz R, Castellano G, et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 2006;12(12):1805–1812
49.
Angelico M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato MF, et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007;46(6):1009–1017
50.
Berenguer M, Aguilera V, Rubin A, Ortiz C, Jimenez M, Prieto M. Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy. J Hepatol 2012;56(6):1310–1316
51.
Samonakis DN, Germani G, Burroughs AK. Immunosuppression and HCV recurrence after liver transplantation. J Hepatol 2012;56(4):973–983
52.
Berenguer M, Aguilera V, Prieto M, San Juan F, Rayon JM, Benlloch S, et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006;44(4):717–722
53.
Vivarelli M, Burra P, La Barba G, Canova D, Senzolo M, Cucchetti A, et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol 2007;47(6):793–798
54.
Papatheodoridis GV, Davies S, Dhillon AP, Teixeira R, Goulis J, Davidson B, et al. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation. 2001;72(3):412–418
55.
Samonakis DN, Mela M, Quaglia A, Triantos CK, Thalheimer U, Leandro G, et al. Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis. Transpl Infect Dis Off J Transplant Soc 2006;8(1):3–12
56.
Brillanti S, Vivarelli M, De Ruvo N, Aden AA, Camaggi V, D'Errico A, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 2002;8(10):884–888
57.
Zervos XA, Weppler D, Fragulidis GP, Torres MB, Nery JR, Khan MF, et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998;65(8):1044–1046
58.
Ghobrial RM, Farmer DG, Baquerizo A, Colquhoun S, Rosen HR, Yersiz H, et al. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Sur 1999;229(6):824–831 (discussion 31-3)
59.
O'Leary JG, Trotter JF, Neri MA, Jennings LW, McKenna GJ, Davis GL, et al. Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantation. Proceedings 2011;24(3):187–191
60.
Llado L, Fabregat J, Castellote J, Ramos E, Xiol X, Torras J, et al. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 2008;14(12):1752–1760
61.
Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 2007;13(11):1521–1531
62.
Hibi T, Shinoda M, Itano O, Obara H, Kitago M, Abe Y, et al. Steroid minimization immunosuppression protocol using basiliximab in adult living donor liver transplantation for hepatitis C virus-related cirrhosis. Hepatol Res Off J Jpn Soc Hepatol 2015;45(12):1178–1184
63.
Filipponi F, Callea F, Salizzoni M, Grazi GL, Fassati LR, Rossi M, et al. Double-blind comparison of hepatitis C histological recurrence Rate in HCV + Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 2004;78(10):1488–1495
64.
Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Thuluvath PJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 2008;14(4):512–525
65.
Ghanekar A, Kashfi A, Cattral M, Selzner N, McGilvray I, Selzner M, et al. Routine induction therapy in living donor liver transplantation prevents rejection but may promote recurrence of hepatitis C. Transplant Proc 2012;44(5):1351–1356
66.
Manns MP, Markova AA, Calle Serrano B, Cornberg M. Phase III results of boceprevir in treatment naive patients with chronic hepatitis C genotype 1. Liver Int Off J Int Assoc Study Liver 2012;32 Suppl 1:27–31
67.
McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New Engl J Med 2009;360(18):1827–1838
68.
Jothimani D, Chandy GM, Conjeevaram H. A new era in the treatment of chronic hepatitis C infection. Indian J Gastroenterol Off J Indian Soc Gastroenterol 2013;32(2):71–79
69.
Coilly A, Dumortier J, Botta-Fridlund D, Latournerie M, Leroy V, Pageaux GP, et al. Multicenter experience with boceprevir or telaprevir to treat hepatitis C recurrence after liver transplantation: when present becomes past, what lessons for future? PloS One 2015;10(9):e0138091
70.
Herzer K, Papadopoulos-Kohn A, Achterfeld A, Canbay A, Piras-Straub K, Paul A, et al. Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant. World J Hepatol 2015;7(9):1287–1296
71.
Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011;54(1):20–27
72.
Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Konigsrainer A, Malek NP, et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 2012;18(12):1464–1470
73.
Gane EJ, Agarwal K. Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: “a flood of opportunity". Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 2014;14(5):994–1002
74.
Charlton M, Gane E, Manns MP, Brown RS, Jr., Curry MP, Kwo PY, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015;148(1):108–117
75.
Saab S, Greenberg A, Li E, Bau SN, Durazo F, El-Kabany M, et al. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. Liver Int Off J Int Assoc Study Liver 2015;35(11):2442–2447
76.
Brown RS, Jr., O'Leary JG, Reddy KR, Kuo A, Morelli GJ, Burton JR, Jr., et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 2016;22(1):24–33
77.
Shinoda M, Ebinuma H, Itano O, Yamagishi Y, Obara H, Kitago M, et al. Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation. Hepatol Res Off J Jpn Soc Hepatol 2016
78.
Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, Jr., et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149(3):649–659
79.
Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016
80.
Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology 2016
81.
Kwo P, Michael W. Fried, K. Rajender Reddy, Consuelo, Soldevila-Pico et al. Dacltasvir and sofosbuvir in patients with recurrent HCV following liver transplantation and advanced fibrosis and cirrhosis: US multicenter treatment protocol. Hepatology 2015; 62 Number 1(Suppl) 321A (abstract 217)
82.
Herzer, Tania M. Welzel, Peter Ferenci, Joerg Petersen, Michael Gschwantler, Markus Cornberg et al. Daclatasvir in combination with sofosbuvir with or without ribavirin is safe and efficacious in liver transplant recipients with HCV recurrence: Interim results of a multicenter compassionate use program. Hepatology 2015; 62 Number 1(Suppl) 304A (abstract 252)
83.
Fontana RJ, Poordad F, Schiff ER et al. Improvement in liver disease parameter following treatment with daclatasvir + sofosbuvir and ribavirin in patients with chronic HCV infection and advanced disease. Hepatology 2015; 62 Number 1(Suppl) 558A (abstract 706)
84.
Beinhardt, Ramona Al Zoairy, ClarissaFreissmuth, Karin Kozbial et al. Efficacy and safety of IFN-free, DAA-based treatment-regimens in patients with HCV-recurrence after liver transplantation: real-life experience from Austria. Hepatology 2015; 62 Number 1(Suppl) 746A (abstract 1092)
85.
Welzel, Rajender Reddy, Michael P. Manns, Flamm et al. Effect of different immunosuppressant regimens on viral kinetics and SVR12 in liver transplant recipients treated with LDV/SOF in the SOLAR trials. Hepatology 2015; 62 Number 1(Suppl) 720A (abstract 1045)
86.
Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, Jr., et al. An interferon-free antiviral regimen for HCV after liver transplantation. New Engl J Med 2014;371(25):2375–2382
87.
Mantry, Robert S. Brown, Jeffrey Enejosa Marina Berenguer, Paul Y. Kwo et al. Ombitasvir/paritaprevir/r and dasabuvir with or without ribavirin for HCV patients with post-transplant recurrence. Hepatology 2015; 62 Number 1(Suppl) 742A (abstract 1084)
88.
Johnson, Alicia B. Lichvar, Vinod K. Rustgi et al. The effect of ledipasvir/sofosbuvir on dose-normalized levels of immunosuppression in liver transplant recipients. Hepatology 2015; 62 Number 1(Suppl) 1057A (abstract 1741)
89.
Tischer S, Fontana RJ. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol 2014;60(4):872–884
90.
Ouwerkerk-Mahadevan S, Snoeys J, Peeters M, Beumont-Mauviel M, Simion A. Drug–drug interactions with the NS3/4A protease inhibitor simeprevir. Clin Pharmacokinet 2016;55(2):197–208
91.
Ouwerkerk-Mahadevan S, Beumont-Mauviel M, Mortier S, Peeters M, Verloes R, Truyers C, et al. Evaluation of the pharmacokinetics and renal excretion of simeprevir in subjects with renal impairment. Drugs R&D 2015;15(3):261–270
92.
Bifano M, Adamczyk R, Hwang C, Kandoussi H, Marion A, Bertz RJ. An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects. Clin Drug Investig 2015;35(5):281–289
93.
Saab, Caroline Huber, Alice Wang, Yuri Sanchez, Timothy R. Juda et al. Lifetime risks of liver morbidity and mortality in patients with recurrent genotype 1 hepatitis C virus infection post-liver transplantation treated with ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin (3D + R) vs former standards of care. Hepatology 2015;62 Number 1(Suppl) 774A (Abstract 1144)
94.
Punzalan CS, Barry C, Zacharias I, Rodrigues J, Mehta S, Bozorgzadeh A, et al. Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant. Clin Transplant 2015;29(12):1105–1111
95.
Shoreibah, DeAnn Jones, Sarah Baggett, Brendan M. McGuire, Omar Massoud. Outcomes of ribavirin free regimens for treatment of recurrent hepatitis C (genotype1) infection post liver transplant. Hepatology 2015; 62 Number 1(Suppl) 790A (abstract 1174)
96.
Fontana RJ, Brown RS, Moreno-Zamora A, Prieto M, Joshi S, Londono MC, et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transplant 2016 22(4):446–458
97.
Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. New Engl J Med 2015;373(27):2608–2617
98.
Welzel TM, David R. Nelson, Giuseppe Morelli, Adrian M. Di Bisceglie, Rajender Reddy et al. Safety and Efficacy of sofosbuvir and ribavirin for the treatment of HCV genotype 2 and 3: results of the HCV-TARGET study. Hepatology 2015; 62 Number 1(Suppl) 727A (abstract 1057)
99.
Patel N, KianBichoupan, Lawrence Ku, RachanaYalamanchili, Alyson Harty, Donald Gardenier et al. Hepatic decompensation and serious adverse events in liver transplant recipients treated with sofosbuvir-containing regimens for recurrent HCV infection. Hepatology 2015; 62 Number 1(Suppl) 795A (abstract 1185)
100.
Saab S, Yuri Sanchez, Caroline Huber, Alice Wang, Timothy R. Juday. The cost-effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin (3D + R) in patients with liver transplantation after genotype 1 hepatitis C virus infection. Hepatology 2015;62 Number 1(Suppl) 923A (abstract 1462)
Metadata
Title
Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review
Authors
Dinesh Jothimani
Sanjay Govil
Mohamed Rela
Publication date
01-09-2016
Publisher
Springer India
Published in
Hepatology International / Issue 5/2016
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-016-9744-3

Other articles of this Issue 5/2016

Hepatology International 5/2016 Go to the issue

Original Article

Renin–angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review

Original Article

Incidence, risk factors and outcomes of acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF) of underlying cirrhosis

Review Article

The role of bile salts in liver regeneration

Original Article

A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment

Editorial

Targeting the renin–angiotensin system in liver fibrosis

Guidelines

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits